| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/20/2000 | WO2000022113A1 ENZYMATIC SYNTHESIS OF ssDNA |
| 04/20/2000 | WO2000021998A1 Bone morphogenetic protein antagonist based on the mature protein |
| 04/20/2000 | WO2000021988A2 Human ankyrin family protein |
| 04/20/2000 | WO2000021987A2 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 04/20/2000 | WO2000021979A2 Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| 04/20/2000 | WO2000021978A2 Laminin 5, 13 and 14 and uses thereof |
| 04/20/2000 | WO2000021963A1 Il-8 receptor antagonists |
| 04/20/2000 | WO2000021953A1 Aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-ht1 receptor antagonists |
| 04/20/2000 | WO2000021951A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 04/20/2000 | WO2000021947A1 Benzazine derivatives as phosphodiesterase 4 inhibitors |
| 04/20/2000 | WO2000021931A1 Ureidopiperidine derivatives as selective human nk3 receptor antagonists |
| 04/20/2000 | WO2000021927A2 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 04/20/2000 | WO2000021926A2 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 04/20/2000 | WO2000021910A2 1,2-disubstituted cyclopropanes |
| 04/20/2000 | WO2000021572A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | WO2000021564A1 Composition and method for treating allergic diseases |
| 04/20/2000 | WO2000021563A1 Remedies or preventives for ischemic reflow failure |
| 04/20/2000 | WO2000021561A1 Model and method for angiogenesis inhibition |
| 04/20/2000 | WO2000021559A2 Blocking factor b to treat complement-mediated immune disease |
| 04/20/2000 | WO2000021542A1 Methods for stimulating bone formation |
| 04/20/2000 | WO2000021538A1 A method of modulating ion channel functional activity |
| 04/20/2000 | WO2000021532A1 Methods for inhibiting bone resorption |
| 04/20/2000 | WO2000021526A1 Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders |
| 04/20/2000 | WO2000021525A2 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 04/20/2000 | WO2000021523A1 Methods for regulating bone formation |
| 04/20/2000 | WO2000021518A1 Drug preparation 'histochrome' for treating ocular conditions |
| 04/20/2000 | WO2000021512A2 Composition and method for treating allergic diseases |
| 04/20/2000 | WO2000021508A2 Novel therapeutic use of compounds with beta-3-agonist activity |
| 04/20/2000 | WO2000021487A2 Formoterol polymorphs |
| 04/20/2000 | WO2000021456A1 Method and device for preparing a dental implant by immersion in a mesenchymal cell culture |
| 04/20/2000 | WO2000007616A3 Use of novel agents inducing cell death in synergy with interferons |
| 04/20/2000 | WO2000005245A3 Inhibitors of urokinase and blood vessel formation |
| 04/20/2000 | WO2000004918A3 Agents for the immunotherapy of tumoral diseases |
| 04/20/2000 | WO2000000622A3 Human oxidoreductase proteins |
| 04/20/2000 | WO1999067407A3 Transgenetic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 04/20/2000 | WO1999066917A3 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 04/20/2000 | WO1999066913A3 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein |
| 04/20/2000 | WO1999066065A3 Proteasomal activity |
| 04/20/2000 | WO1999065571A3 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| 04/20/2000 | WO1999064050A9 Novel potassium channel drugs and their uses |
| 04/20/2000 | WO1999064000A9 Novel therapeutic agents that modulate neurokinin receptors |
| 04/20/2000 | WO1999063981A3 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
| 04/20/2000 | WO1999060986A3 Apoptosis modulators that interact with the huntington's disease gene |
| 04/20/2000 | WO1999058947A9 Modulation of molecular interaction sites on rna and other biomolecules |
| 04/20/2000 | WO1999057266A3 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 04/20/2000 | WO1999054463A3 Human k+ ion channel and therapeutic applications thereof |
| 04/20/2000 | WO1999053078A3 Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
| 04/20/2000 | WO1999048868A9 Heterocyclic classes of compounds for the modulating tyrosine protein kinase |
| 04/20/2000 | DE19847968A1 Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
| 04/20/2000 | DE19845372A1 Verwendung von Katecholderivaten als Proteinaseninhibitoren Using catechol as proteinase inhibitors |
| 04/20/2000 | CA2347653A1 Novel cell signaling polypeptides and nucleic acids |
| 04/20/2000 | CA2347121A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | CA2347113A1 Human ankyrin family protein |
| 04/20/2000 | CA2347092A1 1,2-disubstituted cyclopropanes |
| 04/20/2000 | CA2346943A1 Cyclic tetrapeptide compound and use thereof |
| 04/20/2000 | CA2346729A1 Ureidopiperidine derivatives as selective human nk3 receptor antagonists |
| 04/20/2000 | CA2346689A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 04/20/2000 | CA2346334A1 Composition for treating or preventing ischemia reperfusion injury |
| 04/20/2000 | CA2346329A1 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | CA2346228A1 Composition and method for treating allergic diseases |
| 04/20/2000 | CA2346227A1 Composition and method for treating allergic diseases |
| 04/20/2000 | CA2346155A1 Enzymatic synthesis of ssdna |
| 04/20/2000 | CA2346038A1 Methods for inhibiting bone resorption |
| 04/20/2000 | CA2346036A1 Methods for regulating bone formation |
| 04/20/2000 | CA2346031A1 Methods for stimulating bone formation |
| 04/20/2000 | CA2346008A1 G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 04/20/2000 | CA2344711A1 Expression and secretion of icil-1 receptor antagonist type ii |
| 04/20/2000 | CA2344694A1 Benzazine derivatives as phosphodiesterase 4 inhibitors |
| 04/20/2000 | CA2342314A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 04/19/2000 | EP0994110A1 Sulphonamide derivatives |
| 04/19/2000 | EP0994105A2 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists |
| 04/19/2000 | EP0994102A1 Cyclic derivatives with a cycloalkylenic chain, process for their preparation and pharmaceutical compositions containing them |
| 04/19/2000 | EP0994093A1 Polyhydroxyphenol derivatives and preventive and therapeutic agents for bone and cartilage diseases containing the same |
| 04/19/2000 | EP0993831A2 Compounds and compositions for delivering active agents |
| 04/19/2000 | EP0993613A2 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |
| 04/19/2000 | EP0993468A1 Compositions and methods for activating genes of interest |
| 04/19/2000 | EP0993461A1 New quinoxaline dione derivatives, the production thereof and use of the same in medicaments |
| 04/19/2000 | EP0993460A1 Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 04/19/2000 | EP0993459A1 Compounds useful for inhibition of farnesyl protein transferase |
| 04/19/2000 | EP0993458A1 3-benzylpiperidine |
| 04/19/2000 | EP0993457A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists |
| 04/19/2000 | EP0993456A1 2-substituted 4,5-diaryl imidazoles |
| 04/19/2000 | EP0993455A1 POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO 5,6] CYCLOHEPTA 1,2-b]PYRIDINE |
| 04/19/2000 | EP0993454A1 Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 04/19/2000 | EP0993450A1 New compounds |
| 04/19/2000 | EP0993449A1 Quinoline derivatives as pde iv and/or tnf inhibitors |
| 04/19/2000 | EP0993439A1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 04/19/2000 | EP0993437A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| 04/19/2000 | EP0993433A1 Method for producing calcium pyruvates |
| 04/19/2000 | EP0993304A1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 04/19/2000 | EP0993303A1 Substances in order to achieve preference and create acceptance |
| 04/19/2000 | EP0993301A1 Cocaine receptor binding ligands |
| 04/19/2000 | EP0993300A1 Antithrombotic agents |
| 04/19/2000 | EP0993299A1 N-oxides of heterocyclic esters, amides, thioesters, and ketones |
| 04/19/2000 | EP0880524B1 Adenosin antagonists, method of preparing them and their use as drugs |
| 04/19/2000 | EP0769950A4 Method and compound for the treatment of hair loss |
| 04/19/2000 | EP0738262B1 Novel heterocyclic compounds |
| 04/19/2000 | EP0686144B1 New compounds |
| 04/19/2000 | EP0668769B1 Synthetic compositions related to oak bark extrakt, and method of using same |
| 04/19/2000 | EP0666862B1 6-(substituted methylene) penems and intermediates |